Skip to main content
Menu
search
0
We’re thrilled to announce the appointment of Kenneth Hitchner, BA MBA, as the new Chairman of our Board of Directors. We look forward to leveraging his wealth of strategic advisory, M&A, and transactional expertise to further accelerate the company’s growth as the droplet microfluidic company for single cell analysis and isolation.
Ken Hitchner headshot

Ken brings a wealth of experience to his role as Chairman, with over 30 years of expertise in the healthcare industry. He spent the majority of his career at Goldman Sachs, where he held various leadership positions in the biopharmaceutical and medical device sectors, including Chairman and CEO of Asia Pacific (excluding Japan) from 2013 to 2019, and Global Head of Healthcare banking and Global Co-Head of TMT banking. Prior to joining Goldman Sachs, Ken served as a carrier-based fighter bomber pilot for the U.S. Navy. He currently serves as a Board member of publicly traded companies Wuxi Biologics and CStone Pharmaceuticals, and as a senior advisor to Wuxi Apptec. In addition, he is Chairman of HH&L, a healthcare-focused specialty acquisition company listed on the NYSE, and Cydar Medical, and serves as a senior advisor to early-stage venture capital firm Antler.

Commenting on his appointment, Ken Hitchner said, “Sphere Fluidics is changing the face of cell line development. The Cyto-Mine® platform has transformed single cell analysis and the productivity of biopharmaceutical discovery, maximizing researchers’ productivity in finding rare or valuable cell variants that can lead to a life-changing medicine. I look forward to collaborating with the team as we drive the Company forward in this exciting next phase of commercial growth.”

Dr. Frank F Craig, CEO of Sphere Fluidics, expressed his excitement about Ken’s appointment, stating, “Ken’s expertise in the Financial Services industry is invaluable, and his appointment will be a key asset to our Board. His extensive experience in positioning companies, facilitating significant fund raises, and driving M&A in the Life Sciences arena will greatly contribute to our future plans for building business value and ultimately exiting via a Trade Sale or IPO.”

Welcome to the team Ken – we look forward to achieving our ambitious growth strategy whilst best meeting the needs of our customers together.

About Sphere Fluidics

Sphere Fluidics’ platforms are built on over a decade of scientific and engineering research and development. Originally spun out from the University of Cambridge, we specialize in multiple technical areas to deliver miniaturization.

For further information contact:

news icon

Join our mailing list for updates

Receive latest updates from Sphere Fluidics about new products, special offers and events

You may also like